ESTRO 2024 - Abstract Book

S4881

Physics - Quality assurance and auditing

ESTRO 2024

certain planning aspects (e.g. management of extra cardiac OARs with well-known single-fraction dose limits), but also disagreement in many other points and approaches. To standardize and harmonize STAR, consensus guidelines for numerous aspects of treatment planning including prescribing, documenting, and reporting were now established.

Keywords: STAR, ventricular tachycardia, guidelines

References:

[1] Schmitt D, Blanck O, Gauer T, et al. Technological quality requirements for stereotactic radiotherapy: Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy. Strahlenther Onkol. 2020;196(5):421-443. [2] Lydiard S, Blanck O, Hugo G, et al. A Review of Cardiac Radioablation (CR) for Arrhythmias: Procedures, Technology, and Future Opportunities. Int J Radiat Oncol Biol Phys. 2021;109(3):783-800. [3] Krug D, Blanck O, Andratschke N, et al. Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm. 2021;18(12):2137-2145 [4] Seuntjens J, Lartigau EF, Cora S et al (2014) ICRU report 91. Prescribing, recording, and reporting of stereotactic treatments with small photon beams. J ICRU 14(2):1–160. [5] Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022;112(1):4-21. [6] Diez P, Hanna GG, Aitken KL, et al. UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol). 2022;34(5):288-300. [7] Gerhard SG, Palma DA, Arifin AJ, et al. Organ at Risk Dose Constraints in SABR: A Systematic Review of Active Clinical Trials. Pract Radiat Oncol. 2021;11(4):e355-e365. [8] Haskova J, Jedlickova K, Cvek J, et al. Oesophagopericardial fistula as a late complication of stereotactic radiotherapy for recurrent ventricular tachycardia. Europace. 2022;24(6):969. [9] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med. Phys 2010, 37: 4078-4101. [10] Grehn M, Mandija S, Miszczyk M, et al. Stereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. Europace. 2023;25(4):1284 1295. [11] Zhang DM, Navara R, Yin T, et al. Cardiac radiotherapy induces electrical conduction reprogramming in the absence of transmural fibrosis. Nat Commun. 2021;12:5558. [12] Miszczyk M, Sajdok M, Nożyński J, et al. Histopathological Examination of an Explanted Heart in a Long-Term Responder to Cardiac Stereotactic Body Radiotherapy (STereotactic Arrhythmia Radioablation). Front Cardiovasc Med. 2022;9:1742. [13] Blanck O, Bode F, Gebhard M, et al. Dose-escalation study for cardiac radio-surgery in a porcine model. Int J Radiat Oncol Biol Phys. 2014;89(3):590-98. [14] Krug D, Zaman A, Eidinger L, et al. Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial. Strahlenther Onkol. 2023;199(7):621-630. [15] van der Ree MH, Luca A, Herrera Siklody C, et al. Effects of stereotactic arrhythmia radioablation on left ventricular ejection fraction and valve function over time. Heart Rhythm. 2023:S1547-5271(23)02252-X. [16] Kluge A, Ehrbar S, Grehn M, et al. Treatment Planning for Cardiac Radioablation: Multicenter Multiplatform Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial. Int J Radiat Oncol Biol Phys. 2022;114(2):360-72.